Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

European journal of clinical pharmacology - 1 Sept 2012

Adam de Beaumais Tiphaine, Jacqz-Aigrain Evelyne

Abstract excerpt

BACKGROUND: The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP). Intracellular metabolism of this prodrug is a key component of the therapeutic response. Many metabolizing enzymes are involved in 6-MP disposition and active 6-MP metabolites are represented by 6-thioguanine nucleotides (6-TGN) and methylated metabolites primarily methylated by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Mercaptopurine

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 22421815
DOI: 10.1007/s00228-012-1251-4

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.PMID 22421815Read ↗

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.Semantic proximity Read ↗

Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.Semantic proximity Read ↗

Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase statusSemantic proximity Read ↗

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Semantic proximity Read ↗

Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.Semantic proximity Read ↗

Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.Semantic proximity Read ↗

Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Role of TPMT and ITPA variants in mercaptopurine disposition.Semantic proximity Read ↗

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.